Founded by Assoc. Prof. Neil Frankish
& Assoc. Prof. Helen Sheridan
Trino’s lead candidate has shown excellent activity in pre-clinical models of Inflammatory Bowel Disease, most commonly expressed as ulcerative colitis or Crohn’s disease (CD). First-in-man clinical trials will commence in Q1, 2014.
Founded by Assoc. Prof. John Gilmer
Solvotrin’s lead product ST0702 has major benefits to offer as an anti metastatic agent in colorectal cancer due to its aspirin anti-platelet effects, with additional super-aspirin de-cloaking effects of its lipophilic metabolite.